KP496 is a selective, dual antagonist for the Thromboxane A2 receptor (TP) and the Leukotriene D4 receptor (cysLT1).

KP496 and prednisolone markedly reduce the rise in hydroxyl-L-proline levels in the lung, showing an inhibition ratio of approximately 74% and 63%, respectively, when compared to their own vehicle control groups. Both compounds at doses of KP496 (100 mg/head) and prednisolone (10 mg/kg) significantly decrease the infiltration of total cells, including eosinophils, monocytes/macrophages, and lymphocytes, relative to the control group. Additionally, KP496 at a lower dose (30mg/head) reduces the infiltration of these cell types, except for neutrophils, albeit not significantly. Furthermore, KP496 effectively curtails both acute (day 7) and chronic (day 21) lung inflammation, reducing lymphocyte numbers by day 7 and counts of macrophages, neutrophils, and eosinophils on days 7 and 21.